For the last few years, several clinicopathological characteristics have shown a promising correlation with treatment and prognosis, including EGFR amplification,8 IDH mutation, MGMT promoter methylation status9, 10 and GBM transcriptome subtypes.11, 12 Among all characteristics, patient age seems to be one of the most definitive prognostic factors.13 In clinical practice, we have also found that older patients have worse outcomes than younger ones. This evidence concerns the gene EGFR and glioblastoma.